Increasing data from clinical trials show that when used early in the course of COVID-19, monoclonal antibodies can reduce the need to be admitted to the hospital and decrease the risk of death. For the greatest effect, treatment should be given as soon as possible, ideally within the first week after the start of symptoms.
Under the FDA Emergency Use Authorization, COVID-19 monoclonal antibodies can be used in people who are early in their disease course, not hospitalized for COVID-19, and are at high risk for getting very sick.